Tissue distribution, metabolism and effects of bufotenine administered to rats.
R W Fuller, H D Snoddy, K W Perry
Neuropharmacology July 1, 1995 DOI: 10.1016/0028-3908(95)00049-c (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Rats |
| Intervention | Bufotenine |
| Dose | 1, 30, or 100 mg/kg |
| Duration | 8 hours |
| Citations | 37 |
| Key findings | Bufotenine is rapidly eliminated, partly by type A monoamine oxidase, and penetrates the blood-brain barrier poorly after injection into rats. |
Abstract
Bufotenine (N, N-dimethyl-5-hydroxytryptamine) is a serotonin analog reported to be hallucinogenic. Bufotenine concentrations were measured by liquid chromatography with electrochemical detection after the s.c. injection of bufotenine (1, 30 or 100 mg/kg) into rats. At 1 hr, bufotenine was high in lung, heart and blood and lower in brain and liver. No N-monomethyl-5-hydroxytryptamine was detected, but 5-hydroxyindoleacetic acid (5HIAA) was increased due to bufotenine metabolism. Bufotenine disappeared nearly completely by 8 hr. Bufotenine concentrations were slightly higher in hypothalamus and brain stem than in striatum or cortex; serotonin was slightly decreased, and 5HIAA was increased in these brain regions. Pargyline reduced concentrations of 5HIAA in blood and tissues after bufotenine injection; LY51641 but not deprenyl mimicked pargyline, suggesting type A not type B monoamine oxidase metabolizes bufotenine. Bufotenine injection increased serum corticosterone concentration, an effect not blocked by metergoline at a dose that blocked a similar increase elicited by quipazine. Although only 2% of the serotonin was found in platelet-poor plasma, more than 99% of the bufotenine was found in platelet-poor plasma, indicating that bufotenine is not stored in platelets. These experiments indicate that bufotenine is rapidly eliminated, in part by type A monoamine oxidase, after its injection into rats and that bufotenine penetrates the blood-brain barrier poorly.
Citations in the library
Cited by 21
- Recreational Use, Analysis and Toxicity of Tryptamines Current Neuropharmacology December 10, 2014
- Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. Current Drug Metabolism October 1, 2010
- Metabolism and urinary disposition of N,N‐dimethyltryptamine after oral and smoked administration: a comparative study Drug Testing and Analysis July 28, 2014
- Metabolism and disposition of N,N‐dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca Drug Testing and Analysis April 19, 2012
- Bufo toads and bufotenine: fact and fiction surrounding an alleged psychedelic. Journal of Psychoactive Drugs 1996
and 16 more in the library